Skip to content

Denali Therapeutics Inc. DNLI Compensation and benefits

Compensation and benefits at other companies

Eli Lilly logo
Eli LillyLLY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s compensation and benefits?
Denali Therapeutics Inc. (DNLI) reported compensation and benefits of $9.22M in Q1 2026.
How has Denali Therapeutics Inc.'s compensation and benefits changed year-over-year?
Denali Therapeutics Inc.'s compensation and benefits increased by 20.4% year-over-year, from $7.66M to $9.22M.
What is the long-term trend for Denali Therapeutics Inc.'s compensation and benefits?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s compensation and benefits has grown at a 9.4% compound annual growth rate (CAGR), from $20.5M to $32.18M.